Premium
Skin‐derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis
Author(s) -
SCHALKWIJK J.,
CHANG A.,
JANSSEN P.,
JONGH G.J.,
MIER P.D.
Publication year - 1990
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1990.tb07285.x
Subject(s) - epidermis (zoology) , elastase , psoriasis , cathepsin g , human skin , enzyme , microbiology and biotechnology , biology , chemistry , biochemistry , immunology , anatomy , genetics
SUMMARY Elastase inhibiting activity (EIA) was demonstrated in the epidermis from lesions and in psoriatic scale, whereas normal epidermis did not contain significant EIA. Two new elastase inhibitors were partially purified and characterized using psoriatic scale as a source. The two species (approximate molecular weights 10 and 20 kDa) were shown to be stable, and high‐affinity inhibitors of human leucocyte elastase (K i <10 −10 M). NO activity against human cathepsin G could be demonstrated. Cultured human keratinocytes were shown to contain EIA activity similar to that found in psoriatic scale. EIA could also be demonstrated in human epidermis following the induction of an experimental inflammatory response by sellotape‐stripping. We propose the acronym SKALP (skin‐derived antileucoprotease) as a name for these new proteinases inhibitors.